• Helping those with life threatening diseases

  • Better medicine for aldehyde metabolism disorders

  • Guided by novel scientific research


home page

ALDEA Pharmaceuticals is developing a number of small-molecule modulators of the aldehyde dehydrogenase enzyme (ALDH) superfamily to address significant unmet medical needs.

Latest News

Aldea Pharmaceuticals Closes $24 Million Series B Financing. more...

"Targeting aldehyde dehydrogenase 2: New Therapeutic Opportunities" published in Physiological Reviews

Dr. Richard Shames joins ALDEA Pharmaceuticals as Chief Medical Officer